Madrigal Pharmaceuticals ( MDGL ) only launched Rezdiffra (resmetirom) for nonalcoholic steatohepatitis [NASH] in April 2024, but the drug has already broken through the $100M per quarter mark, with net sales of$137.3M in Q1Scientist and trader of biotech stock. Focus on trading around events such as trial results and NDA/BLA approvals. Also covering companies in industries regulated by the FDA. Articles present my opinion on stocks, but don't constitute investment advice.Analyst’s Disclosure: I/we have no ...